Navigation Links
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Date:12/7/2007

Celldex also receives approval from Health Canada to open clinical sites

and establishes a collaboration with the National Cancer Institute

PHILLIPSBURG, N.J., Dec. 7 /PRNewswire/ -- Celldex Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive form of brain cancer. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII. Celldex Therapeutics announced a definitive merger agreement with AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) in October 2007.

In the ACTIVATE phase IIa study, CDX-110 treated GBM patients showed a median survival time of 30 months, more than a 100 percent increase in survival, versus the historical control's median of 14.5 months. The study has demonstrated a median time-to-progression of 13 months (p=0.0001) versus the historical control's median of 6.4 months. An extension study, ACT II, which combines CDX-110 with chemotherapy in a similar patient population, has not yet reached median time-to-progression or survival. However, preliminary progression free survival (PFS) and overall survival (OS) data in ACT II look very similar to the ACTIVATE experience, and the data suggest that chemotherapy and CDX-110 can be administered concurrently while still maintaining strong immune responses.

In September, Celldex randomized its first patient into ACT III, a definitive Phase II/III randomized study of CDX-110 with radiation and temozolomide in patients with newly-diagnosed GBM. The clinical trial is investigating the anticancer activity, impact on survival, a
'/>"/>

SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)...  BioMed Realty Trust, Inc. (NYSE: ... on life sciences, today announced financial results for ... Third Quarter 2014 Highlights Financial and Operating ... during the quarter representing approximately 657,700 square feet, ... third quarter of approximately 219,700 square feet; and ...
(Date:10/27/2014)... Research and Markets has announced the ... report to their offering. H1N1 influenza (zoonotic) ... of the swine H1N1 virus, known as H1N1v virus. The ... and lungs. H1N1 virus is an RNA virus belonging to ... such as humans, swine, birds, seals, and horses. Influenza A ...
(Date:10/27/2014)... Research and Markets has announced the addition ... report to their offering. A service ... of tasks that might be simple or complex, time-consuming, ... broad divisions: Professional Robot and Personal/domestic Robot. Professional robots ... such as underwater applications, defense, and security and surveillance ...
Breaking Medicine Technology:BioMed Realty Trust Reports Third Quarter 2014 Financial Results 2BioMed Realty Trust Reports Third Quarter 2014 Financial Results 3BioMed Realty Trust Reports Third Quarter 2014 Financial Results 4BioMed Realty Trust Reports Third Quarter 2014 Financial Results 5BioMed Realty Trust Reports Third Quarter 2014 Financial Results 6BioMed Realty Trust Reports Third Quarter 2014 Financial Results 7BioMed Realty Trust Reports Third Quarter 2014 Financial Results 8BioMed Realty Trust Reports Third Quarter 2014 Financial Results 9BioMed Realty Trust Reports Third Quarter 2014 Financial Results 10BioMed Realty Trust Reports Third Quarter 2014 Financial Results 11BioMed Realty Trust Reports Third Quarter 2014 Financial Results 12BioMed Realty Trust Reports Third Quarter 2014 Financial Results 13BioMed Realty Trust Reports Third Quarter 2014 Financial Results 14BioMed Realty Trust Reports Third Quarter 2014 Financial Results 15BioMed Realty Trust Reports Third Quarter 2014 Financial Results 16BioMed Realty Trust Reports Third Quarter 2014 Financial Results 17BioMed Realty Trust Reports Third Quarter 2014 Financial Results 18BioMed Realty Trust Reports Third Quarter 2014 Financial Results 19BioMed Realty Trust Reports Third Quarter 2014 Financial Results 20BioMed Realty Trust Reports Third Quarter 2014 Financial Results 21Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3Global Service Robot Market 2014-2018: Key Vendors are GeckoSystem, Honda Motor, iRobot and Toyota Motor 2Global Service Robot Market 2014-2018: Key Vendors are GeckoSystem, Honda Motor, iRobot and Toyota Motor 3
... N.C. , April 22 The reporting of ... pharmaceutical industry and its importance is clear as the U.S. ... for adverse events. Yet when it comes to gray areas ... A Best Practices, LLC post-marketing surveillance study found that 50 ...
... /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing,developer, ... (the "PRC"), today reported it will exhibit at the 63rd,PHARMCHINA. , , ... Venue: International Convention ... , , ...
Cached Medicine Technology:Best Practices, LLC Report on Post-Marketing Surveillance Programs Sheds Light on Gray Areas of Adverse Event Reporting 2Best Practices, LLC Report on Post-Marketing Surveillance Programs Sheds Light on Gray Areas of Adverse Event Reporting 3Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA 2
(Date:10/29/2014)... certain prostate cancer medications are linked with an increased ... congestive heart failure or prior heart attacks. Published in ... and patients weigh the benefits and risks of the ... levels of male hormones in the body to prevent ... treatment for prostate cancer. Despite its anticancer effects, ADT ...
(Date:10/28/2014)... that aims to make personalized medicine a reality for ... across British Columbia. , The "Genomics for Precision Drug ... of its kind in North America. The project is ... (BCPhA), with the research component led by a team ... Sciences (UBC). It will position the pharmacist as the ...
(Date:10/28/2014)... Uppsala University demonstrate that elderly men with self-reported ... Alzheimer,s disease than men without self-reported sleep disturbances. ... Alzheimer,s & Dementia . , The researchers ... 50 year old, between the years 1970 and ... self-reported sleep disturbances were linked to an increased ...
(Date:10/27/2014)... from Massachusetts General Hospital (MGH) investigators has identified ... activity of a key brain region in patients ... a mechanism of action behind one of the ... therapy. They also found evidence that pretreatment ... which patients are likely to respond to that ...
(Date:10/27/2014)... adopt a new therapy by watching others use it, ... , New technology is like an influential colleague -- ... reminded every five to seven days , CHICAGO ... when they are persuaded to do so by an influential ... adopting innovations also have relevance for business, education and research. ...
Breaking Medicine News(10 mins):Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:Genomics helps pharmacists target the right drugs for the right patient 2Health News:PET scans reveal how psychodynamic therapy for depression may change brain function 2Health News:PET scans reveal how psychodynamic therapy for depression may change brain function 3Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3
... recent study accepted for publication in The Endocrine Society,s ... found that postmenopausal women who smoke have higher androgen ... levels being highest in heavy smokers. Previous studies ... are potential risk factors for breast and endometrial cancer ...
... FOR AUG. 31, 2011, ARLINGTON, Va.] Immunizations, including ... protect children from life-threatening pneumonia, according to new guidelines ... Infectious Diseases Society of America (IDSA)., The guidelines, which ... (CAP) in infants and children, place preventing bacterial pneumonia ...
... Research in Marketing Science by Professor Kamel Jedidi, ... Business School; Professor Oded Netzer, Philip H. Geier ... Professor Ricardo Montoya, Department of Industrial Engineering, University ... can maximize the return on marketing investments ...
... Aug. 30 (HealthDay News) -- Nearly one in 10 women in ... new study finds, and they could face a slightly higher risk ... doesn,t prove that so-called "child marriage" causes the increased risk of ... September issue of the journal Pediatrics . Still, the ...
... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay ... panel began a two-day meeting Tuesday on silicone breast ... post-approval safety studies. After being banned for 14 ... silicone gel-filled breast implants for breast reconstructive surgery and ...
... More and more, patients show up to appointments with hypertension ... products that they hope will help lower their blood pressure. ... products will do any good, or if they will cause ... shift where an increasing number of people want to avoid ...
Cached Medicine News:Health News:Smoking after menopause may increase sex hormone levels 2Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 2Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 3Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 4Health News:Research identifies marketing mix strategy for pharmaceutical firms 2Health News:Women Married Before Age 18 at Higher Risk of Mental Woes: Study 2Health News:Women Married Before Age 18 at Higher Risk of Mental Woes: Study 3Health News:FDA Focuses on Silicone Breast Implant Safety Studies 2Health News:FDA Focuses on Silicone Breast Implant Safety Studies 3Health News:Beyond pills: Cardiologists examine alternatives to halt high blood pressure 2Health News:Beyond pills: Cardiologists examine alternatives to halt high blood pressure 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: